Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 17Terminated 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

venetoclax 38Azacitidine 24fludarabine 20Cytarabine 18Cyclophosphamide 16Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5Decitabine 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Exercise 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Everolimus × Other hematologic neoplasm × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡